Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

News in AL Amyloidosis ASH 2016

News in AL Amyloidosis ASH 2016 Amyloidosis is a rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most interesting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and the efficacy of a multiple drug regimen in light-chain (AL) amyloidosis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

News in AL Amyloidosis ASH 2016

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/news-in-al-amyloidosis-ash-2016-ROj7b18Q08
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0332-6
Publisher site
See Article on Publisher Site

Abstract

Amyloidosis is a rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most interesting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and the efficacy of a multiple drug regimen in light-chain (AL) amyloidosis.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: May 24, 2017

References

  • Primary systemic amyloidosis: clinical and laboratory features in 474 cases
    Kyle, RA; Gertz, MA
  • Update on treatment of light chain amyloidosis
    Mahmood, S; Palladini, G; Sanchorwala, V
  • Molecular mechanism s of amyloidosis
    Merlini, G; Belotti, V
  • Light chain amyloidosis: the heart of the problem
    Merlini, G; Palladini, G
  • Systemic light chain amyloidosis an update for treating physicians
    Merlini, G; Wechalekar, AD; Palladini, G
  • Amyloidosis where are we now and where are we heading?
    Picken, MM
  • Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimen
    Vrana, JA; Gamez, JD; Madden, BJ
  • Reliable typing of systemic amyloidosis through proteomic analysis of subcutaneous adipose tissue
    Brambilla, F; Lavatalli, F; Silvestre, D
  • Serum cardiac troponins and N‑terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Dispenzieri, A; Gertz, MA; Kyle, RA
  • Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Kumar, S; Dispenzieri, A; Lacy, MQ
  • Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
    Merlini, G; Lousada, I; Ando, Y
  • A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
    Palladini, G; Hegenbart, U; Milani, P
  • Challenges of Using NT-ProBNP for response assessment in aystemic AL amyloidosis – Analysis of a prospective study
    Wechalekar, A; Foard, D; Whelan, C
  • Growth Differentiation Factor-15 (GDF-15) Is a new biomarker with independent prognostic significance for survival and renal outcomes in different cohorts of patients with light chain (AL) Amyloidosis
    Kastritis, E; Merlini, G; Papassotiriou, I
  • Treatment of immunoglobulin light chain amyloidosis
    Dispenzieri, A; Buadl, F; Kumar, SK
  • A randomized phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with AL Amyloidosis
    Kastritis, E; Leleu, X; Arnulf, B
  • Bortezomib-containing regimens for the treatment of newly diagnosed AL Amyloidosis
    Alahwal, H; Song, KW; Duggan, P
  • Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
    Palladini, G; Milani, P; Foli, A
  • Bortezomib versus non-Bortezomib based treatment for transplant ineligible patients with light chain Amyloidosis
    Sidana, S; Tandon, N; Dispenzieri, A
  • Treatment with Bortezomib-based therapy followed by Autologous stem cell transplantation improves outcomes in light chain Amyloidosis
    Jain, T; Kung, ST; Shah, V
  • Results of 25 patients from a multicenter, multinational, prospective phase II study of Bortezomib based induction treatment followed by Autologous stem cell transplantation in patients with newly diagnosed Al Amyloidosis
    Minnema, M; Nasserinejad, K; Hazenberg, B
  • Standard dose versus risk adapted Melphalan conditioning on outcomes in systemic AL Amyloidosis patients undergoing frontline autologous stem cell transplant based on revised mayo stage
    Tandon, N; Sidana, S; Dispenzieri, A
  • Predictors of Early Relapse (ER) following initial therapy for systemic immunoglobulin light chain Amyloidosis
    Tandon, N; Sidana, S; Gertz, MA
  • Patterns of relapse after upfront therapy in AL Amyloidosis
    Milani, P; Basset, M; Russo, F
  • Practice patterns of re-initiation of therapy at time of relapse or progression post-autologous stem cell transplant among patients with AL Amyloidosis
    Hwa, YL; Warsame, R; Gertz, MA
  • Final results of a phase 2 study of Bendamustine in combination with Dexamethasone in patients with previously treated systemic light-chain Amyloidosis
    Lagos, GG; Lentzsch, S; Comenzo, RL
  • Safety and efficacy of Carfilzomib in previously treated systemic light-chain Amyloidosis
    Cohen, AD; Landau, H; Scott, EC
  • Hematologic responses and cardiac organ improvement in patients with heavily pretreated cardiac immunoglobulin light chain (AL) Amyloidosis receiving Daratumumab
    Kaufmann, G; Witteles, R; Wheeler, M
  • First-in-human phase I/II study of NEOD001 in patients with light chain Amyloidosis and persistent organ dysfunction
    Gertz, MA; Landau, H; Commenzo, RL
  • NEOD001 demonstrates organ biomarker responses in patients with light chain Amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase 1/2 study
    Gertz, MA; Comenzo, RL; Landau, H
  • Analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL Amyloidosis
    Edwards, CV; Gould, J; Langer, AL
  • Therapeutic clearance of Amyloid by antibodies to serum Amyloid P component
    Richards, DB; Cookson, LM; Berges, AC